These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 18328900)

  • 21. Observations on the mechanism of omalizumab as a steroid-sparing agent in autoimmune or chronic idiopathic urticaria and angioedema.
    Dreyfus DH
    Ann Allergy Asthma Immunol; 2008 Jun; 100(6):624-5. PubMed ID: 18592835
    [No Abstract]   [Full Text] [Related]  

  • 22. A critical appraisal of omalizumab as a therapeutic option for chronic refractory urticaria/angioedema.
    Lang DM
    Ann Allergy Asthma Immunol; 2014 Apr; 112(4):276-9. PubMed ID: 24589165
    [No Abstract]   [Full Text] [Related]  

  • 23. Effective treatment of refractory severe heat urticaria with omalizumab.
    Bullerkotte U; Wieczorek D; Kapp A; Wedi B
    Allergy; 2010 Jul; 65(7):931-2. PubMed ID: 19930230
    [No Abstract]   [Full Text] [Related]  

  • 24. Immunological effects of omalizumab in chronic urticaria: a case report.
    Iemoli E; Piconi S; Fusi A; Borgonovo L; Borelli M; Trabattoni D
    J Investig Allergol Clin Immunol; 2010; 20(3):252-4. PubMed ID: 20635791
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antihistamine-resistant urticaria factitia successfully treated with anti-immunoglobulin E therapy.
    Krause K; Ardelean E; Kessler B; Magerl M; Metz M; Siebenhaar F; Weller K; Worm M; Zuberbier T; Maurer M
    Allergy; 2010 Nov; 65(11):1494-5. PubMed ID: 20560911
    [No Abstract]   [Full Text] [Related]  

  • 26. IgE and D-dimer baseline levels are higher in responders than nonresponders to omalizumab in chronic spontaneous urticaria.
    Cugno M; Genovese G; Ferrucci S; Casazza G; Asero R; Marzano AV
    Br J Dermatol; 2018 Sep; 179(3):776-777. PubMed ID: 29582427
    [No Abstract]   [Full Text] [Related]  

  • 27. Omalizumab for chronic urticaria.
    Casale TB
    J Allergy Clin Immunol Pract; 2014; 2(1):118-9. PubMed ID: 24565785
    [No Abstract]   [Full Text] [Related]  

  • 28. Maintenance of remission with low-dose omalizumab in long-lasting, refractory chronic urticaria.
    Romano C; Sellitto A; De Fanis U; Esposito G; Arbo P; Giunta R; Lucivero G
    Ann Allergy Asthma Immunol; 2010 Jan; 104(1):95-7. PubMed ID: 20143654
    [No Abstract]   [Full Text] [Related]  

  • 29. The clinical response to omalizumab in chronic spontaneous urticaria patients is linked to and predicted by IgE levels and their change.
    Ertas R; Ozyurt K; Atasoy M; Hawro T; Maurer M
    Allergy; 2018 Mar; 73(3):705-712. PubMed ID: 29083482
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Chronic urticaria: omalizumab and review of therapeutic options.
    Bergstrom KG
    J Drugs Dermatol; 2013 Jun; 12(6):715-6. PubMed ID: 23839196
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Omalizumab in chronic urticaria.
    Metz M; Maurer M
    Curr Opin Allergy Clin Immunol; 2012 Aug; 12(4):406-11. PubMed ID: 22766620
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Chronic Idiopathic Urticaria.
    Wu EY; Saini SS
    J Allergy Clin Immunol Pract; 2015; 3(6):1003-4; quiz 105. PubMed ID: 26553623
    [No Abstract]   [Full Text] [Related]  

  • 33. Total IgE levels are linked to the response of chronic spontaneous urticaria patients to omalizumab.
    Weller K; Ohanyan T; Hawro T; Ellrich A; Sussman G; Koplowitz J; Gimenez-Arnau AM; Peveling-Oberhag A; Staubach P; Metz M; Maurer M
    Allergy; 2018 Dec; 73(12):2406-2408. PubMed ID: 30076605
    [No Abstract]   [Full Text] [Related]  

  • 34. Omalizumab therapy in three patients with chronic autoimmune urticaria.
    Al-Ahmad M
    Ann Saudi Med; 2010; 30(6):478-81. PubMed ID: 20864790
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Extraordinary response to omalizumab in a child with severe chronic urticaria.
    Asero R; Casalone R; Iemoli E
    Eur Ann Allergy Clin Immunol; 2014 Jan; 46(1):41-2. PubMed ID: 24702874
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Serial D-dimer plasma levels in a patient with chronic spontaneous urticaria developing resistance to omalizumab.
    Asero R
    Clin Exp Dermatol; 2017 Aug; 42(6):667-669. PubMed ID: 28691309
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Omalizumab in Chronic Spontaneous Urticaria: A Brazilian Real-Life Experience.
    Ensina LF; Valle SO; Juliani AP; Galeane M; Vieira dos Santos R; Arruda LK; Melo JM; de Souza PK; Serpa FS; de Andrade DM; França AT; Campos RA; Camelo-Nunes I; Solé D
    Int Arch Allergy Immunol; 2016; 169(2):121-4. PubMed ID: 27055122
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Outcomes of using omalizumab for more than 1 year in refractory chronic urticaria.
    Har D; Patel S; Khan DA
    Ann Allergy Asthma Immunol; 2015 Aug; 115(2):126-9. PubMed ID: 26093778
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dermatologic uses of omalizumabtitle.
    Chia JC; Mydlarski PR
    J Dermatolog Treat; 2017 Jun; 28(4):332-337. PubMed ID: 27759482
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Successful treatment of a bullous urticaria with omalizumab.
    Ozturk AB; Kocaturk E; Ozturk E
    Allergol Int; 2014 Sep; 63(3):495-7. PubMed ID: 24957115
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.